2.1 Hypertension Guidelines, Staging & Primary Regimens

Hypertension Guidelines, Staging, and First-Line Pharmacotherapy

Hypertension is the leading modifiable risk factor for cardiovascular disease (CVD), stroke, heart failure, and end-stage kidney disease. For the Board Certified Ambulatory Care Pharmacist (BCACP), mastering the nuance of blood pressure (BP) assessment, guideline-directed staging thresholds, cardiovascular risk stratification, and patient-specific pharmacotherapy is essential for clinical practice and board examinations.

---

Blood Pressure Measurement & Diagnostic Classification

Accurate diagnosis requires standardized blood pressure measurement technique. Patients must be seated quietly with back supported and feet flat on the floor for at least 5 minutes prior to measurement, having avoided caffeine, exercise, and nicotine for ≥30 minutes. An appropriately sized cuff must be used (bladder length encircling 75% to 100% of arm circumference; bladder width ≥40% of arm circumference) positioned at mid-sternum (heart level). An average of two or more readings obtained on two or more clinical encounters is required to establish a clinical diagnosis.

To confirm elevated office readings and rule out white-coat hypertension (elevated clinic BP with normal out-of-office BP) or identify masked hypertension (normal clinic BP with elevated out-of-office BP), guidelines strongly endorse 24-hour Ambulatory Blood Pressure Monitoring (ABPM) or standardized Home Blood Pressure Monitoring (HBPM).

Blood Pressure Classification (ACC/AHA)

Note: When systolic and diastolic pressures fall into discordant categories, the higher category determines the stage.

---

Target Blood Pressure Goals

Supported by the landmark SPRINT trial (Systolic Blood Pressure Intervention Trial), which demonstrated significant reductions in composite major adverse cardiovascular events (MACE) and all-cause mortality with intensive systolic BP lowering, current clinical guidelines recommend a uniform target:

$\text{Target BP Goal: } <130/80\text{ mmHg}$

This target applies to:

• General adults with established hypertension
• Patients with clinical Atherosclerotic Cardiovascular Disease (ASCVD)
• Patients with Type 1 or Type 2 Diabetes Mellitus
• Patients with Chronic Kidney Disease (CKD Stages 1–5, non-dialysis)
• Older ambulatory community-dwelling adults ($\ge 65$ years of age)
• Patients with estimated 10-year ASCVD risk $\ge 10%$

---

Nonpharmacologic Lifestyle Interventions

Lifestyle modifications represent foundational therapy for all patients with elevated BP or hypertension, capable of producing cumulative systolic BP reductions:

1. DASH Dietary Pattern: Diet rich in fruits, vegetables, whole grains, and low-fat dairy with reduced saturated fat ($-11\text{ mmHg}$).
2. Dietary Sodium Restriction: Target $<1,500\text{ mg/day}$ (or at least a $1,000\text{ mg/day}$ reduction) ($-5\text{ to }-6\text{ mmHg}$).
3. Potassium Supplementation: Target $3,500\text{--}5,000\text{ mg/day}$ through dietary sources, unless contraindicated by CKD or hyperkalemia-inducing medications ($-4\text{ to }-5\text{ mmHg}$).
4. Physical Activity: 90–150 minutes/week of moderate-to-vigorous aerobic exercise plus dynamic resistance training ($-4\text{ to }-8\text{ mmHg}$).
5. Weight Loss: Approximately $1\text{ mmHg}$ SBP reduction per $1\text{ kg}$ weight lost in overweight/obese individuals.
6. Alcohol Moderation: Men $\le 2$ standard drinks/day; women $\le 1$ standard drink/day ($-4\text{ mmHg}$).

---

First-Line Pharmacotherapeutic Drug Classes

Four primary drug classes are established as first-line agents based on proven reductions in cardiovascular morbidity and mortality: Thiazide/Thiazide-like Diuretics, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), and Dihydropyridine Calcium Channel Blockers (DHP CCBs).

1. Thiazide & Thiazide-Like Diuretics

• Mechanism of Action: Inhibit the $\text{Na}^+/\text{Cl}^-$ symporter in the distal convoluted tubule (DCT), promoting natriuresis, lowering plasma volume acutely, and decreasing systemic vascular resistance chronically.
• Agents & Dosing:
  • Chlorthalidone: 12.5–25 mg orally once daily (long half-life: 40–60 hours; high potency).
  • Indapamide: 1.25–2.5 mg orally once daily (metabolically neutral; effective at lower eGFR).
  • Hydrochlorothiazide (HCTZ): 12.5–50 mg orally once daily (shorter half-life: 6–12 hours; weaker 24-hour ambulatory BP control).
• Clinical Pearl & Comparison: Chlorthalidone and indapamide are preferred over HCTZ due to superior clinical trial evidence (e.g., ALLHAT, SHEP, HYVET) demonstrating stronger 24-hour BP reduction and cardiovascular protection. Chlorthalidone is 1.5 to 2 times more potent than HCTZ on a milligram-for-milligram basis.
• Electrolyte & Metabolic Side Effects:
  • Decreases: Hypokalemia, hypomagnesemia, hyponatremia.
  • Increases: Hypercalcemia, hyperuricemia (may precipitate acute gout flares), hyperglycemia, dyslipidemia.
  • Renal Limitation: Thiazide diuretics lose efficacy as monotherapy when eGFR drops $<30\text{ mL/min}/1.73\text{m}^2$; loop diuretics (e.g., furosemide, torsemide) are preferred for volume management in severe CKD.

2. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

ACE Inhibitors

• Agents: Lisinopril (10–40 mg daily), Enalapril (5–40 mg daily in 1–2 divided doses), Ramipril (2.5–20 mg daily).
• Mechanism: Inhibit angiotensin-converting enzyme, preventing conversion of Angiotensin I to Angiotensin II; inhibits degradation of bradykinin and substance P.
• Adverse Effects & Monitoring:
  • Dry, Non-Productive Cough: Occurs in 5% to 20% of patients due to bradykinin/substance P accumulation in the pulmonary tree. Not dose-dependent; requires class switch to an ARB.
  • Angioedema: Rapid swelling of lips, tongue, pharynx, or bowel wall. Highest incidence in Black patients and smokers. Absolute contraindication to future ACE inhibitor therapy; requires a 36-hour washout period before starting an ARNI (sacubitril/valsartan).
  • Hyperkalemia: Due to suppressed aldosterone secretion; increased risk with CKD, diabetes, potassium supplements, or potassium-sparing diuretics.
  • Hemodynamic Elevation in Serum Creatinine: Transient increase in SCr up to 30% from baseline is expected and acceptable due to dilation of the efferent arteriole reducing intraglomerular pressure.
• Contraindications: Pregnancy (teratogenic / fetal renal dysgenesis), history of ACEi-induced angioedema, bilateral renal artery stenosis, concurrent use with aliskiren in patients with diabetes.

Angiotensin II Receptor Blockers (ARBs)

• Agents: Losartan (50–100 mg daily in 1–2 divided doses), Valsartan (80–320 mg daily), Olmesartan (20–40 mg daily), Telmisartan (40–80 mg daily), Candesartan (8–32 mg daily).
• Mechanism: Selectively block the $\text{AT}_1$ receptor, preventing Angiotensin II-mediated vasoconstriction and aldosterone release without inhibiting bradykinin breakdown.
• Key Distinctions: ARBs carry an extremely low incidence of cough and significantly lower risk of cross-reactive angioedema (<2.5%).
• Unique Drug Safety Warning: Olmesartan is associated with sprue-like enteropathy, characterized by severe chronic diarrhea, profound weight loss, and duodenal villous atrophy on biopsy occurring months to years after initiation. Symptoms resolve upon olmesartan discontinuation.
• Dual RAAS Blockade Warning: Combining an ACEi with an ARB or direct renin inhibitor (aliskiren) is strictly contraindicated; trials (ONTARGET, ALTITUDE) proved dual blockade increases the risk of hyperkalemia, acute kidney injury, and syncope without additional cardiovascular benefit.

3. Calcium Channel Blockers (CCBs)

Dihydropyridines (DHPs)

• Agents: Amlodipine (2.5–10 mg once daily), Nifedipine ER (30–90 mg once daily), Felodipine (2.5–10 mg once daily).
• Mechanism: Selectively inhibit L-type calcium channels on vascular smooth muscle, causing arterial vasodilation with minimal direct effect on cardiac conduction.
• Adverse Effects:
  • Peripheral Dependent Edema: Dose-dependent (higher at 10 mg amlodipine). Mediated by precapillary arteriolar dilation and fluid extravasation into interstitial spaces—not systemic fluid overload. Therefore, it does not respond well to loop diuretics; co-administration of an ACEi or ARB dilates post-capillary venules, significantly reducing DHP-induced edema.
  • Reflex Tachycardia, Dizziness, Flushing, Gingival Hyperplasia.

Non-Dihydropyridines (Non-DHPs)

• Agents: Diltiazem CD/ER (120–360 mg daily), Verapamil SR/ER (120–480 mg daily).
• Mechanism: Inhibit L-type calcium channels on both vascular smooth muscle and cardiac myocytes/nodal tissue, resulting in negative inotropic, chronotropic, and dromotropic effects.
• Adverse Effects & Interactions: Bradycardia, heart block, constipation (especially verapamil), worsening heart failure symptoms.
• Contraindications: Heart Failure with reduced Ejection Fraction (HFrEF, LVEF <40%) due to negative inotropic depression.
• Cytochrome P450 Drug Interactions: Both diltiazem and verapamil are moderate-to-strong inhibitors of CYP3A4 and P-glycoprotein (P-gp), significantly increasing serum levels of simvastatin, lovastatin, cyclosporine, tacrolimus, apixaban, rivaroxaban, and digoxin.

---

Treatment Selection & Clinical Decision Pathways

Initial Monotherapy vs. Upfront Combination Therapy

• Stage 1 Hypertension (BP 130–139/80–89 mmHg with ASCVD risk $\ge 10%$): Initiate monotherapy with any first-line agent (thiazide-like diuretic, DHP CCB, or ACEi/ARB).
• Stage 2 Hypertension (BP $\ge 140/90\text{ mmHg}$ and $\ge 20/10\text{ mmHg}$ above goal): Initiate upfront combination therapy with two first-line agents of different classes (e.g., ACEi/ARB + DHP CCB, or ACEi/ARB + Thiazide diuretic). Utilizing Single-Pill Combinations (SPCs) drastically enhances medication adherence and accelerates time to BP control.

Compelling Clinical Indications & Demographic Considerations

+-----------------------------------------------------------------------------+
|                        PATIENT-SPECIFIC FIRST-LINE CHOICES                  |
+------------------------------------+----------------------------------------+
| Clinical Scenario                  | Preferred First-Line Antihypertensives |
+------------------------------------+----------------------------------------+
| Black Adults (without CKD)         | DHP CCB or Thiazide Diuretic           |
|                                    | (Superior stroke/CVD reduction vs ACEi)|
+------------------------------------+----------------------------------------+
| CKD Stage 3-5 OR CKD with          | ACE Inhibitor or ARB                   |
| Albuminuria (uACR >= 300 mg/g)     | (Slows CKD progression; nephroprotective|
+------------------------------------+----------------------------------------+
| Diabetes with Albuminuria          | ACE Inhibitor or ARB                   |
| (uACR >= 30 mg/g)                  |                                        |
+------------------------------------+----------------------------------------+
| Ischemic Heart Disease / Post-MI   | Beta-Blocker (Carvedilol, Metoprolol   |
|                                    | Succinate) + ACEi/ARB                  |
+------------------------------------+----------------------------------------+
| HFrEF (LVEF <= 40%)                | ARNI/ACEi/ARB + Evidence-based BB +    |
|                                    | MRA + SGLT2i (Avoid Non-DHP CCBs)      |
+------------------------------------+----------------------------------------+
| Pregnancy (or childbearing potential| Labetalol, Nifedipine ER, Methyldopa   |
| without contraception)             | (ACEi, ARB, ARNI, Aliskiren CONTRAIND) |
+------------------------------------+----------------------------------------+

---

Monitoring & Follow-Up Protocol

• Following initiation or titration of antihypertensive therapy, patients should return for clinical evaluation, BP measurement, and laboratory assessment (electrolytes and serum creatinine) in 2 to 4 weeks.
• Once target blood pressure (<130/80 mmHg) is attained, follow-up intervals may be spaced to every 3 to 6 months.